The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Letter to the Editor
Editor, – The article by Professor Gallus (Aust Prescr 2010;33:42–7) discussed the clinical applications of the new oral anticoagulants – rivaroxaban and dabigatran. In those patients who had had hip or knee replacements, the new drugs were started either 6–8 hours after wound closure or 1–4 hours after surgery. Would Professor Gallus kindly give his advice to orthopaedic surgeons for those patients who have had a previous deep vein thrombosis or who possess one of the inherited thrombotic tendencies such as Factor V Leiden mutation.
Clinical haematologist and Consultant physician
Waikiki Private Hospital